425 related articles for article (PubMed ID: 32333818)
1. COVID-19: lambda interferon against viral load and hyperinflammation.
Andreakos E; Tsiodras S
EMBO Mol Med; 2020 Jun; 12(6):e12465. PubMed ID: 32333818
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
3. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Park A; Iwasaki A
Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
[TBL] [Abstract][Full Text] [Related]
4. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.
Nile SH; Nile A; Qiu J; Li L; Jia X; Kai G
Cytokine Growth Factor Rev; 2020 Jun; 53():66-70. PubMed ID: 32418715
[TBL] [Abstract][Full Text] [Related]
5. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
6. Type 1 interferons as a potential treatment against COVID-19.
Sallard E; Lescure FX; Yazdanpanah Y; Mentre F; Peiffer-Smadja N
Antiviral Res; 2020 Jun; 178():104791. PubMed ID: 32275914
[TBL] [Abstract][Full Text] [Related]
7. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SARS-CoV-2 by type I and type III interferons.
Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
[TBL] [Abstract][Full Text] [Related]
9. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
Front Immunol; 2020; 11():588724. PubMed ID: 33117402
[TBL] [Abstract][Full Text] [Related]
10. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
Saul S; Einav S
ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
[TBL] [Abstract][Full Text] [Related]
11. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
12. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
13. Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
O'Brien TR; Thomas DL; Jackson SS; Prokunina-Olsson L; Donnelly RP; Hartmann R
Clin Infect Dis; 2020 Sep; 71(6):1410-1412. PubMed ID: 32301957
[No Abstract] [Full Text] [Related]
14. Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications.
Allegra A; Di Gioacchino M; Tonacci A; Musolino C; Gangemi S
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640747
[TBL] [Abstract][Full Text] [Related]
15. Interplay between SARS-CoV-2 and the type I interferon response.
Sa Ribero M; Jouvenet N; Dreux M; Nisole S
PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
[TBL] [Abstract][Full Text] [Related]
16. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
Theoharides TC
Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
[No Abstract] [Full Text] [Related]
17. Working Hypothesis for Glucose Metabolism and SARS-CoV-2 Replication: Interplay Between the Hexosamine Pathway and Interferon RF5 Triggering Hyperinflammation. Role of BCG Vaccine?
Laviada-Molina HA; Leal-Berumen I; Rodriguez-Ayala E; Bastarrachea RA
Front Endocrinol (Lausanne); 2020; 11():514. PubMed ID: 32733388
[No Abstract] [Full Text] [Related]
18. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F
Clin Immunol; 2020 Jun; 215():108450. PubMed ID: 32360516
[TBL] [Abstract][Full Text] [Related]
19. Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation.
Yang D; Chu H; Hou Y; Chai Y; Shuai H; Lee AC; Zhang X; Wang Y; Hu B; Huang X; Yuen TT; Cai JP; Zhou J; Yuan S; Zhang AJ; Chan JF; Yuen KY
J Infect Dis; 2020 Aug; 222(5):734-745. PubMed ID: 32563187
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of two human-to-human transmitted coronaviruses: Corona Virus Disease 2019 vs. Middle East Respiratory Syndrome Coronavirus.
Xu P; Sun GD; Li ZZ
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5797-5809. PubMed ID: 32495918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
